H

Hepion Pharmaceuticals

HEPA

0.78110
USD
0.0111
(1.44%)
Market Closed
Volume
55
EPS
0
Div Yield
0
P/E
-0
Market Cap
3,711,441
Related Instruments
A
ADVM
0.09000
(1.21%)
7.53000 USD
A
AGIO
-1.950
(-4.20%)
44.520 USD
G
GTHX
-0.11000
(-2.56%)
4.19000 USD
R
RDHL
0.37050
(97.30%)
0.75130 USD
News

Title: Hepion Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.